Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Healthcare should be accessible for all: development of the ObServation Tool and Resource for Inclusive Communication in Healthcare (OSTRICH).

Disability and rehabilitation·2026

Same author

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

ESMO open·2026

Same author

Lung cancer research and treatment: global perspectives and strategic calls to action.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

An interprofessional clinic for adults with Turner syndrome: the patient perspective.

Climacteric : the journal of the International Menopause Society·2022

Same author

Corrigendum to "The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study" [Int J Obstet Anesth. 2021;47:102983].

International journal of obstetric anesthesia·2022

Same author

The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study.

International journal of obstetric anesthesia·2021

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Published on: May 25, 2022

Genetically engineered Newcastle disease virus for malignant melanoma therapy.

D Zamarin¹, A Vigil, K Kelly

¹Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. dmitriy.zamarin@mssm.edu

|February 27, 2009

Summary

A novel oncolytic Newcastle disease virus (NDV) engineered to express interleukin-2 (IL-2) demonstrates potent anti-melanoma activity. This enhanced NDV effectively clears tumors and improves survival in preclinical models, offering a promising new cancer therapy.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jun 25, 2026

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid

Published on: May 25, 2022

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

Oncology
Virology
Immunotherapy

Background:

Malignant melanoma remains a therapeutic challenge due to poor response to conventional chemotherapy.
Current systemic therapies like interferon and interleukin-2 (IL-2) have limitations including significant side effects.
Oncolytic viruses, specifically Newcastle disease virus (NDV), are being explored as alternative cancer treatments.

Purpose of the Study:

To investigate the efficacy of a recombinant NDV engineered to express IL-2 for malignant melanoma therapy.
To evaluate the oncolytic potential and immunomodulatory effects of IL-2-expressing NDV against melanoma.

Main Methods:

Development of a recombinant NDV expressing murine IL-2.
Assessment of cytolytic activity against various melanoma cell lines in vitro.
Evaluation of therapeutic efficacy in a syngeneic murine melanoma model, including tumor clearance and survival analysis.

Main Results:

Recombinant NDV exhibited significant cytolytic effects on multiple melanoma cell lines.
IL-2-expressing NDV demonstrated effectiveness in clearing established syngeneic melanoma tumors in mice.
Enhanced viral therapy led to improved animal survival and induced antitumor immunity.

Conclusions:

Recombinant IL-2-expressing NDV is a potent agent against malignant melanoma in preclinical studies.
The enhanced oncolytic and immunomodulatory properties warrant further investigation for human melanoma treatment.